Life Insurance With Diabetes

Life insurance with diabetes is available — and for many applicants, it is more affordable than they expect. The persistent belief that a diabetes diagnosis means uninsurable or prohibitively expensive coverage is one of the most consequential misconceptions in personal financial planning, because it causes many people with manageable conditions to forgo protection their families genuinely need. The reality is that insurance carriers evaluate diabetes through a detailed, clinical lens that distinguishes between very different presentations of the same diagnosis: a 45-year-old with well-controlled Type 2 diabetes on oral medication, no complications, and consistent A1C readings in a favorable range may qualify for standard or near-standard rates. A 35-year-old with Type 1 diabetes using an automated insulin delivery system, documented physician compliance, and no diabetic complications has more carrier options than most people realize. And even applicants whose management has been imperfect — those with higher A1C readings, a history of fluctuating control, or mild complications — still have meaningful options through carriers that specialize in rated and impaired-risk underwriting.

The single most important variable in life insurance underwriting for any diabetic applicant is not the diagnosis itself but the evidence of management. Underwriters are evaluating risk over a 20- or 30-year coverage period. An applicant who can demonstrate consistent A1C control, regular physician follow-up, medication adherence, stable blood pressure and cholesterol, and no hospitalizations for diabetic emergencies is presenting a fundamentally different risk profile than one who cannot document these factors — even if both carry the same diagnosis. This is why carrier selection and application strategy matter so much for diabetic applicants: submitting to the wrong carrier with the wrong presentation produces either a decline or an unnecessarily high table rating, while submitting to the right carrier with a well-documented file produces an outcome that may surprise the applicant favorably. At Diversified Insurance Brokers, we specialize in exactly this kind of carrier-matching and application strategy for impaired-risk life insurance cases.

This page covers the life insurance underwriting landscape for diabetic applicants in full practical detail: how carriers evaluate the condition, what factors drive favorable and unfavorable outcomes, how Type 1 and Type 2 are treated differently, how the recent shift in underwriting treatment of GLP-1 medications affects applicants using them, what complications do to ratings, and how to structure the strongest possible application regardless of where your diabetes management currently stands. For the foundational context on how high-risk applicants generally navigate the life insurance market, our resource on high-risk life insurance covers the full impaired-risk landscape, and our high-risk life insurance playbook covers the strategic framework for impaired-risk placement. If you have already been declined, our guide on what to do after a life insurance denial explains the pathways that remain open and why a different carrier with the right presentation often produces a different outcome.

How Insurance Companies Evaluate Diabetes — The Modern Framework

The life insurance underwriting framework for diabetes has evolved significantly over the past decade. Carriers that once applied rigid, categorical rules based on diagnosis type alone now use nuanced, multi-factor scoring models that weight treatment adherence, complication history, A1C trend, concurrent health factors, and management technology alongside the basic diagnosis. This shift reflects a medical reality that the insurance industry has been slow but increasingly willing to acknowledge: modern diabetes management — through continuous glucose monitoring, automated insulin delivery systems, GLP-1 and other medication classes, and more rigorous lifestyle management — produces outcomes that are meaningfully better than what older actuarial data assumed. Applicants who can document that their diabetes is being managed with the tools and disciplines available in the current medical environment are presenting a different risk profile than the cohort on which older underwriting tables were built.

The practical result is that an independent broker who understands which carriers have updated their diabetic underwriting guidelines most favorably — and who knows how to present an application to maximize the weight given to positive management factors — can often produce meaningfully better outcomes than an applicant receives by submitting to a single carrier through a direct channel. Underwriting is not just a medical assessment; it is a financial and actuarial judgment call that different carriers make differently. Two carriers given identical applicant information about a 50-year-old with Type 2 diabetes and a recent A1C of 7.2 may produce rate quotes that differ by one or more table ratings — which can translate to substantial premium differences for the same coverage amount. This carrier disparity is why the choice of broker and the strategic selection of which carriers to approach is as important as the underlying health facts themselves.

Key Underwriting Factors for Diabetic Applicants

These factors reflect general underwriting patterns across the life insurance market. Individual carrier guidelines vary, and outcomes depend on the specific combination of factors in any applicant’s profile. Table rating thresholds and A1C benchmarks differ by carrier. Always work with an independent broker who can match your specific profile to the most favorable underwriting environment available for your situation.

Type 2 Diabetes — The Path to Affordable Coverage

Type 2 diabetes, particularly when managed with oral medications and no documented complications, represents the most accessible underwriting scenario for diabetic applicants. Carriers across the market have recognized that a well-managed Type 2 diabetic — consistent A1C readings in a controlled range, stable blood pressure and cholesterol, healthy BMI, regular physician oversight, and no complications — represents a meaningfully different risk than the actuarial models from prior decades assumed. Many carriers now offer standard or near-standard rates to qualifying Type 2 diabetics, and some carriers with favorable underwriting guidelines can consider preferred rates for Type 2 applicants who meet specific criteria around age at diagnosis (typically after 40), A1C consistency (generally under 7.0), management method (dietary management or metformin only), and overall health profile.

The management method matters significantly in how carriers score the application. An applicant controlling Type 2 diabetes through diet and exercise alone — with documented A1C consistency — presents the most favorable profile in most carrier systems. Applicants using metformin as the sole medication are still considered strong candidates and represent the majority of well-rated Type 2 diabetic approvals. Applicants using two oral medications or a GLP-1 agonist alongside metformin occupy a middle ground — still competitive for standard rates at many carriers, particularly when A1C is stable and no complications exist. Applicants requiring insulin for Type 2 control face more selective underwriting and are typically table-rated to some degree, though the presence or absence of complications and the insulin regimen’s effectiveness (as demonstrated by A1C stability) remains the primary driver of how high the rating falls. For Type 2 applicants over age 50 or 60, our resource on life insurance over 50 covers how age and health intersect in underwriting decisions for this demographic.

Type 1 Diabetes — Higher Scrutiny, Not Automatic Decline

Type 1 diabetes requires more careful carrier selection because fewer carriers actively compete for this underwriting segment with competitive pricing. Type 1 involves insulin dependency from the outset, typically earlier age of diagnosis, and a longer cumulative duration of exposure to the condition — all factors that contribute to higher statistical risk profiles in actuarial models. However, the underwriting landscape for Type 1 has improved materially in recent years as carriers have begun incorporating data from modern management technologies into their risk models. Applicants using continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems — such as closed-loop insulin pump and CGM combinations — can in some cases demonstrate a level of glycemic control that was not achievable with traditional insulin management, and some carriers are beginning to credit this documentation favorably.

For Type 1 applicants, the factors that matter most are the absence of complications and the stability of long-term management. A Type 1 diabetic who has lived with the condition for 20 or 30 years without developing retinopathy, neuropathy, nephropathy, or cardiovascular complications presents a very different actuarial picture than statistical averages for the Type 1 population suggest, and carriers with sophisticated underwriting processes for this segment can differentiate that risk. A1C consistency matters as much as the specific level — an applicant with an A1C of 7.2 that has been stable for two or more years is underwritten more favorably than one whose A1C fluctuated between 6.5 and 9.0 in the same period. The application strategy for Type 1 diabetics should involve careful carrier selection, complete medical documentation going back several years, and an experienced broker who knows which carriers are most likely to price this risk favorably given the specific combination of factors in play. Our life insurance with pre-existing conditions resource covers the broader framework for high-scrutiny underwriting scenarios.

GLP-1 Medications and the Shifting Underwriting Landscape

One of the most significant developments in life insurance underwriting for diabetic applicants over the past several years is the industry’s evolving view of GLP-1 receptor agonist medications — the drug class that includes semaglutide and tirzepatide, marketed under brand names including Ozempic, Wegovy, Mounjaro, and Zepbound. Initially approved for Type 2 diabetes management, these medications have demonstrated outcomes beyond glycemic control: significant weight reduction, favorable effects on cardiovascular risk markers, and in clinical trials, measurable reductions in major cardiovascular events in high-risk populations. Large reinsurance studies analyzing millions of covered lives have found consistent GLP-1 use associated with materially reduced cardiovascular event rates, a finding that is now beginning to influence how leading carriers treat applicants who are prescribed these medications.

The practical underwriting implication is that an applicant with Type 2 diabetes who is taking a GLP-1 agonist and can demonstrate favorable outcomes — improved or stable A1C, documented weight reduction, stable cardiovascular markers — is increasingly being viewed as a lower-risk profile than older underwriting models assumed for any insulin-related medication. Some carriers are now explicitly treating GLP-1 agonist use with documented response as a neutral-to-positive underwriting factor rather than a negative one. This shift is not yet universal across the market — underwriting guidelines vary significantly by carrier — but it represents a meaningful improvement in the landscape for diabetic applicants on this medication class. Applicants taking GLP-1 agonists should document their treatment response comprehensively and work with a broker who knows which carriers have incorporated the most current data into their underwriting guidelines. This is an area where the right carrier selection can produce materially different outcomes for the same applicant profile.

Complications — The Factor That Changes Everything

Of all the variables in diabetic life insurance underwriting, the presence or absence of diabetes-related complications is the one that most dramatically affects the range of available outcomes. An applicant with well-controlled diabetes but no complications occupies an entirely different underwriting space than an applicant with the same A1C level who has developed any of the major complications associated with chronic hyperglycemia. Complications signal that the condition has already produced organ damage, which creates actuarial implications that cannot be offset by improved management after the fact. The major complications that underwriters evaluate are diabetic neuropathy (peripheral nerve damage producing numbness, pain, or loss of sensation, typically in the feet and hands), diabetic retinopathy (damage to the blood vessels in the retina, affecting vision), and diabetic nephropathy (kidney involvement, evidenced by microalbuminuria or proteinuria on urine testing).

Each complication adds table ratings to the underwriting outcome. Minor neuropathy without autonomic involvement may add one or two table steps. Retinopathy at early stages may add one to three table steps depending on progression. Nephropathy — even microalbuminuria without overt proteinuria — is a significant rating factor because it signals renal involvement that can progress to chronic kidney disease. Peripheral vascular disease or a history of cardiovascular events (heart attack, stroke, angina) carries substantial additional rating or may produce a decline depending on recency and current status. Applicants with multiple complications face either high table ratings that make coverage expensive or outright declines for traditional fully-underwritten coverage — at which point simplified issue or guaranteed issue products become the appropriate pathway. Our guide on life insurance for heart disease covers how cardiovascular complications intersect with diabetic underwriting outcomes, as these conditions frequently co-occur.

Table Ratings — How Substandard Classification Affects Premiums

When a diabetic applicant does not qualify for standard rates, the typical outcome is a table rating — a classification in the substandard tier that adjusts the premium upward from the standard rate by a defined percentage per table step. Most carriers structure table ratings with each step adding approximately 25% to the standard rate premium. An applicant rated Table 2 pays approximately 50% more than the standard rate for the same coverage. An applicant rated Table 4 pays approximately twice the standard rate. An applicant rated Table 8 — the highest table at most carriers — pays approximately three times the standard rate. The specific table assigned reflects the carrier’s assessment of the combined risk from all underwriting factors, with A1C level, complication status, management method, concurrent health conditions, and age at diagnosis all contributing to the scoring.

Because different carriers apply different table rating systems and different weights to the same risk factors, the same diabetic applicant may receive a Table 2 offer from one carrier and a Table 4 offer from another. This disparity is not uncommon in impaired-risk underwriting and underscores why submitting to multiple qualified carriers — through an independent broker who understands the diabetic underwriting guidelines at each — consistently produces better outcomes than any single-carrier approach. For applicants who have previously been declined or received very high table ratings, our resource on what to do after a life insurance denial covers the full landscape of re-application strategy, informal pre-underwriting, and alternative coverage pathways. Our life insurance for colon cancer resource provides a parallel example of how another serious health condition navigates the rated and impaired-risk market.

Policy Types Available for Diabetic Applicants

The type of life insurance product that is most appropriate for a diabetic applicant depends on both their underwriting outcome and their coverage objective. Term life insurance — providing a defined death benefit for a fixed period at a level premium — is the most commonly evaluated structure for diabetic applicants seeking income replacement, mortgage protection, or dependent support. Many diabetic applicants with controlled Type 2 qualify for traditional term life insurance at standard or table-rated premiums, and term products across multiple time horizons are available. For coverage needs tied to specific financial obligations, our resources across different term lengths provide context for matching coverage duration to planning objectives: our guides on 10-year term, 15-year term, 20-year term, 25-year term, and 30-year term options cover each period in detail, along with the full range of specialty terms from 1 year and 5 year short-term options through longer commitments of 35 years, 40 years, and 50 years for those seeking extended protection.

Permanent life insurance — whole life or universal life — provides lifelong coverage with premium and benefit stability, and builds cash value over time. For diabetic applicants whose condition may make future coverage difficult to obtain, the permanent structure eliminates the re-underwriting risk that exists at the end of a term period. Once issued, the policy cannot be cancelled for health reasons as long as premiums are paid, and premiums cannot increase based on health deterioration. An applicant who secures a permanent policy when their diabetes is controlled — even at a table rating — has locked in lifelong coverage at a known cost, protecting against the scenario where A1C worsens or complications develop over time. Our resource on converting term to permanent life insurance covers the conversion option that allows some term policyholders to transition to permanent coverage without new medical underwriting — a particularly valuable feature for diabetic applicants who obtained term coverage when their health was more favorable.

Simplified Issue and Burial Insurance for Diabetic Applicants

When traditional fully-underwritten life insurance is either unavailable or priced beyond reach due to a combination of uncontrolled diabetes, multiple complications, or other concurrent health factors, simplified issue and guaranteed issue products provide coverage alternatives that should not be overlooked. Simplified issue life insurance typically involves a health questionnaire without a full medical exam — applicants answer a series of health questions, and coverage is offered or declined based on those answers without requiring lab work or detailed medical records. For diabetic applicants whose primary concerns are not a complex cardiac history or end-stage organ complications, simplified issue products can provide meaningful coverage amounts at accessible pricing.

Guaranteed issue life insurance provides coverage without any health questions — acceptance is guaranteed for qualifying applicants within the eligible age range, regardless of health status. The trade-offs are smaller available benefit amounts, typically limited to amounts appropriate for final expense coverage, and graded benefit structures that pay reduced benefits if the insured passes away within the first two or three years of the policy. For diabetic applicants who cannot qualify for any other coverage, guaranteed issue provides a floor of protection that ensures family members are not left with no coverage at all. Our resource on burial insurance for higher-risk applicants covers the final expense insurance landscape in detail, including how guaranteed issue and simplified issue structures are typically structured and sized for this use case.

How to Prepare the Strongest Possible Application

Preparation is the most controllable variable in a diabetic applicant’s life insurance outcome. The underwriting file you present — the completeness, currency, and consistency of your medical documentation — significantly influences how a carrier’s underwriter interprets the risk. Before submitting any application, gather 12 to 24 months of A1C lab results showing the trend in your glycemic control. Collect records of all physician and endocrinologist visits, including dates, findings, and treatment recommendations. Document your current medication list and any changes in medication within the past 12 months with the clinical rationale for each change. Gather annual eye exam results and any ophthalmology notes if retinopathy screening has been performed. Confirm current urinalysis and kidney function lab results showing the absence of microalbuminuria if possible. Ensure any continuous glucose monitoring data or automated insulin delivery device data is available, as some carriers are beginning to incorporate this documentation into their evaluation.

Timing matters as well. An applicant whose A1C has been improving over the past 12 months should present that trend as prominently as possible; an applicant whose most recent A1C is significantly better than historical readings should allow sufficient time for the improved level to be reflected in at least two or three consecutive lab results before applying. A single improved A1C reading is less persuasive than a sustained trend. Conversely, an applicant whose most recent reading was significantly higher than their historical norm may benefit from allowing their management to stabilize before applying — a temporary spike is still an A1C on the medical record that underwriters will see. The strategic timing of an application relative to medical documentation history is one of the practical advantages of working with an experienced impaired-risk broker who understands how underwriting decisions are actually made. Our resource on how much life insurance do I need helps determine the coverage target before beginning the application process.